Skip Navigation

JNCI Journal of the National Cancer Institute 2009 101(11):769; doi:10.1093/jnci/djp174
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Multitype L2 Fusion Protein Vaccines for HPV

Current vaccines for human papillomavirus (HPV) are based on viral capsid L1 proteins and are HPV type-restricted. To determine whether L2 capsid proteins, which induce antibodies that neutralize several HPV types, would be good candidates for broad spectrum HPV vaccines, Jagu et al. (p. 782) vaccinated mice and rabbits with various HPV-16 L2 polypeptides and fusion proteins comprising L2 protective epitopes derived from several medically relevant HPV genotypes in various adjuvants or with a negative control. Both mice and rabbits vaccinated with concatenated multitype L2 fusion protein vaccines generated neutralizing antibody responses . . . [Full Text of this Article]

The Role of CIP2A and MYC in Gastric Cancer

Risks of Second Cancers in Survivors of Pediatric Cancer

Diagnostic Interpretive Variability Among Mammography Facilities

RasGAP-Derived Peptide and Tumor Growth in Mice


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?